Clinomics announced on the 14th that it has signed a business agreement with Easygnome, a microbiome analysis specialist company, to commercialize the 'Pet Genetic (DNA) and Gut Microbiome Testing Service' business.
Easygnome aims to develop microbiome-based therapeutics and specializes in human microbiome analysis technology using third-generation genome sequencing (NGS) methods, as well as the development of individually recognized probiotic strains.
The microbiome (gut microorganisms) is invisible to the naked eye but is called the "third organ of the human body." It not only helps nutrients consumed to be absorbed efficiently but also produces essential nutrients that the human body cannot make and defends against pathogenic microorganisms such as viruses and bacteria from invading our body.
Clinomics, which launched Dog Nomics, the best pet genome DNA test in Korea, will, through this business agreement with Easygnome, develop a genetic testing platform using pet microbiome and DNA tests and establish pet gut microbiome-based services. It will build a system for pet health status, disease prediction, and diagnosis to promote commercialization.
In addition, it plans to accelerate the development of various applied products effective for extreme diseases and extreme aging with scientific evidence by developing technology applicable not only to pets but also to humans.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
